The Breakroom's Episode 1, Chapter 1 focuses on how the development of the biomarker landscape has dramatically improved personalized treatment strategies for lung cancer patients due to the amount of information that oncologists can access.
The vast volume of information creates complexity and diverse needs for each case; however, a few things remain true in cancer care: information must be easy to obtain and interpret to enable multidisciplinary discussions to get the patients on the right therapy.
Oncologists are also facing challenges with the scarcity of sufficient tissue specimens for a broad range of biomarker testing. In fact, tissue quantity not being sufficient (QNS) can be as high as 30% in lung cancer cases. This impact on cancer care has advanced the testing approach to include liquid biopsy as a tenable option for broad biomarker testing in lung cancer.